|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: INAVA |
Gene summary for INAVA |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | INAVA | Gene ID | 55765 |
| Gene name | innate immunity activator | |
| Gene Alias | C1orf106 | |
| Cytomap | 1q32.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q3KP66 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55765 | INAVA | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.00e-05 | -1.62e-01 | 0.294 |
| 55765 | INAVA | HTA11_99999971662_82457 | Human | Colorectum | MSS | 4.07e-04 | -1.62e-01 | 0.3859 |
| 55765 | INAVA | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.62e-04 | -1.62e-01 | 0.3005 |
| 55765 | INAVA | A002-C-114 | Human | Colorectum | FAP | 3.98e-03 | -1.62e-01 | -0.1561 |
| 55765 | INAVA | A002-C-016 | Human | Colorectum | FAP | 1.10e-02 | -1.00e-01 | 0.0521 |
| 55765 | INAVA | S027 | Human | Liver | HCC | 9.45e-26 | 1.20e+00 | 0.2446 |
| 55765 | INAVA | S028 | Human | Liver | HCC | 1.59e-44 | 1.33e+00 | 0.2503 |
| 55765 | INAVA | S029 | Human | Liver | HCC | 2.07e-32 | 1.20e+00 | 0.2581 |
| 55765 | INAVA | Pat01-B | Human | Stomach | GC | 7.16e-30 | 5.14e-01 | 0.5754 |
| 55765 | INAVA | Pat02-B | Human | Stomach | GC | 2.05e-17 | 2.82e-01 | 0.0368 |
| 55765 | INAVA | Pat03-B | Human | Stomach | GC | 8.94e-22 | 4.16e-01 | 0.3693 |
| 55765 | INAVA | Pat04-B | Human | Stomach | GC | 1.02e-11 | 2.67e-01 | -0.1483 |
| 55765 | INAVA | Pat05-B | Human | Stomach | GC | 1.84e-08 | 3.13e-01 | -0.0353 |
| 55765 | INAVA | Pat06-B | Human | Stomach | GC | 1.49e-20 | 3.46e-01 | -0.1961 |
| 55765 | INAVA | Pat07-B | Human | Stomach | GC | 5.61e-12 | 5.03e-01 | 0.0935 |
| 55765 | INAVA | Pat09-B | Human | Stomach | GC | 1.27e-07 | 1.95e-01 | -0.0359 |
| 55765 | INAVA | Pat10-B | Human | Stomach | GC | 7.31e-08 | 3.98e-01 | 0.084 |
| 55765 | INAVA | Pat11-B | Human | Stomach | GC | 2.02e-16 | 4.09e-01 | -0.182 |
| 55765 | INAVA | Pat12-B | Human | Stomach | GC | 1.47e-14 | 3.00e-01 | 0.0325 |
| 55765 | INAVA | Pat13-B | Human | Stomach | GC | 3.92e-11 | 3.11e-01 | 0.0555 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
| GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
| GO:00452169 | Cervix | CC | cell-cell junction organization | 53/2311 | 200/18723 | 3.83e-08 | 2.53e-06 | 53 |
| GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
| GO:00018197 | Cervix | CC | positive regulation of cytokine production | 95/2311 | 467/18723 | 4.88e-07 | 1.85e-05 | 95 |
| GO:00022379 | Cervix | CC | response to molecule of bacterial origin | 78/2311 | 363/18723 | 5.55e-07 | 2.06e-05 | 78 |
| GO:00310988 | Cervix | CC | stress-activated protein kinase signaling cascade | 58/2311 | 247/18723 | 8.02e-07 | 2.89e-05 | 58 |
| GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
| GO:00514038 | Cervix | CC | stress-activated MAPK cascade | 55/2311 | 239/18723 | 2.96e-06 | 8.31e-05 | 55 |
| GO:00703027 | Cervix | CC | regulation of stress-activated protein kinase signaling cascade | 46/2311 | 195/18723 | 9.35e-06 | 2.11e-04 | 46 |
| GO:00018949 | Cervix | CC | tissue homeostasis | 57/2311 | 268/18723 | 2.43e-05 | 4.21e-04 | 57 |
| GO:00434104 | Cervix | CC | positive regulation of MAPK cascade | 90/2311 | 480/18723 | 2.92e-05 | 4.83e-04 | 90 |
| GO:00328727 | Cervix | CC | regulation of stress-activated MAPK cascade | 44/2311 | 192/18723 | 3.09e-05 | 5.10e-04 | 44 |
| GO:00431228 | Cervix | CC | regulation of I-kappaB kinase/NF-kappaB signaling | 53/2311 | 249/18723 | 4.50e-05 | 6.87e-04 | 53 |
| GO:00602498 | Cervix | CC | anatomical structure homeostasis | 63/2311 | 314/18723 | 6.03e-05 | 8.68e-04 | 63 |
| GO:00022212 | Cervix | CC | pattern recognition receptor signaling pathway | 39/2311 | 172/18723 | 1.08e-04 | 1.38e-03 | 39 |
| GO:00072497 | Cervix | CC | I-kappaB kinase/NF-kappaB signaling | 56/2311 | 281/18723 | 1.81e-04 | 2.12e-03 | 56 |
| GO:00027534 | Cervix | CC | cytoplasmic pattern recognition receptor signaling pathway | 18/2311 | 60/18723 | 2.26e-04 | 2.55e-03 | 18 |
| GO:00725939 | Cervix | CC | reactive oxygen species metabolic process | 47/2311 | 239/18723 | 7.74e-04 | 6.87e-03 | 47 |
| GO:00026973 | Cervix | CC | regulation of immune effector process | 62/2311 | 339/18723 | 9.25e-04 | 7.84e-03 | 62 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |